JB Chemicals Gets Go-Ahead to Sell Antidepressant in the US

JB Chemicals and Pharmaceuticals Ltd has received approval from the US Food and Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Amitriptyline Hydrochloride Tablets. This approval allows the company to market its generic version of the antidepressant in the United States, further strengthening its international presence.

 

Key Highlights:

The company has been investing in a diversified pipeline and contract development and manufacturing operations, which has helped drive its recent financial performance.

In the quarter ending March 2025, JB Chemicals reported a 15.5% year-on-year rise in net profit to ₹145.7 crore, with revenues up 10.2% to ₹949.5 crore.

 

The company’s shares saw positive movement following the announcement, reflecting investor confidence in its global expansion strategy.

 

Source: Business Standard, Indian Pharma Post, Moneycontrol, CNBC-TV18, EquityBulls